# A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

> **NCT04254107** · PHASE1 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 133 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Gastric Carcinoma
- Gastroesophageal Junction Carcinoma
- Classical Hodgkin Lymphoma
- Diffuse Large B-cell Lymphoma
- Peripheral T-cell Lymphoma
- Cutaneous Melanoma
- Head and Neck Squamous Cell Carcinoma
- Bladder Cancer
- Ovarian Cancer
- Triple Negative Breast Cancer
- Cervical Cancer

## Interventions

- **DRUG:** SEA-TGT
- **DRUG:** sasanlimab
- **DRUG:** brentuximab vedotin

## Key facts

- **NCT ID:** NCT04254107
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-29
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 133 (ACTUAL)
- **Why stopped:** Study closed due to portfolio prioritization
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04254107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04254107, "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04254107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*